1. NAME OF THE MEDICINAL PRODUCT
Zidoval 7.5 mg/g vaginal gel

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Metronidazole 0.75% w/w, 7.5 mg/g

Excipients with known effect:
Methyl parahydroxybenzoate (E218) 0.8 mg/g
Propyl parahydroxybenzoate (E216) 0.2 mg/g
Propylene glycol (E1520) 30.0 mg/g.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Vaginal gel.

A colourless to straw coloured gel.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Zidoval vaginal gel is indicated for the treatment of bacterial vaginosis.

4.2 Posology and method of administration
For vaginal administration.

Adults
One application of Zidoval vaginal gel (5g) inserted into the vagina once daily, at bedtime, for 5 consecutive days.

Elderly
Bacterial vaginosis is not commonly seen in the elderly population and consequently clinical assessment in this age group has not been carried out.

Pediatric population
Not recommended for use in children and adolescents under 18 years since safety and efficacy have not been established.

Method of administration
Pierce sealed end of tube and screw open end of applicator tightly onto tube of gel. Squeeze tube, filling the applicator with gel. Remove applicator from tube and gently insert applicator into vagina as far as it will comfortably go. Push the plunger to release the gel. Dispose of applicator as instructed.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to other nitroimidazoles or parabens.

4.4 Special warnings and precautions for use
Use during menses is not recommended.

Known or previously unrecognised candidiasis may present more prominent symptoms during therapy with Zidoval vaginal gel and may require treatment with a candicidal agent.
Metronidazole is a nitroimidazole and should be used with care in patients with evidence of a history of blood dyscrasias.

As with all vaginal infections, sexual intercourse during the infection and during treatment with Zidoval vaginal gel is not recommended.

Zidoval contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Zidoval also contains propylene glycol which may cause skin irritation.

4.5 Interaction with other medicinal products and other forms of interaction
Oral metronidazole has been associated with a disulfiram-like reaction in combination with alcohol.
Acute psychotic reactions and confusion have occurred during concomitant use of disulfiram with oral metronidazole. At the low serum concentrations, which result from the use of Zidoval vaginal gel, the possibility of similar reactions is unlikely although cannot be excluded.
Oral metronidazole has been shown to increase the plasma concentrations of warfarin, lithium, cyclosporin and 5-fluorouracil. Similar effects after vaginal administration of metronidazole are not expected due to the low plasma concentrations but cannot be completely ruled out.
Metronidazole may interfere with certain types of determination of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactic dehydrogenase (LDH), triglycerides and hexokinase glucose. Values of zero may be observed.

4.6 Fertility, pregnancy and lactation

Pregnancy
Data on a large number (several hundred) of exposed pregnancies indicate no adverse effects of metronidazole on the foetus/newborn child. There have been no formal studies with Zidoval vaginal gel in pregnant women. Caution should, therefore, be exercised when prescribing to pregnant women.

Lactation
The ratio of serum concentrations of Zidoval vaginal gel/oral metronidazole is approximately 0.02. Metronidazole is excreted in milk at concentrations similar to those in maternal serum and the ratio of serum concentrations of metronidazole in the breastfed infant/mother is approximately 0.15. Caution should be exercised when prescribing to lactating women.

4.7 Effects on ability to drive and use machines
Zidoval has no influence on the ability to drive and use machines.

4.8 Undesirable effects
In controlled clinical trials involving 759 patients, the most commonly reported ADRs were urogenital (26%) and gastrointestinal (14%).

<table>
<thead>
<tr>
<th>Infections and infestations</th>
<th>Vaginal candidiasis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common (≥1/100, &lt;1/10):</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolism and nutrition disorders</th>
<th>Decreased appetite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common (≥1/100, &lt;1/10):</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psychiatric Disorders</th>
<th>Depression, difficulty sleeping.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon (≥1/1000, &lt;1/100):</td>
<td></td>
</tr>
</tbody>
</table>
### Nervous system disorders

<table>
<thead>
<tr>
<th>Common (≥1/100, &lt;1/10)</th>
<th>Headache, dizziness.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon (≥1/1000, &lt;1/100)</td>
<td>Abnormal sensation of limbs, metallic taste.</td>
</tr>
</tbody>
</table>

### Gastrointestinal disorders

<table>
<thead>
<tr>
<th>Common (≥1/100, &lt;1/10)</th>
<th>GI discomfort/abdominal cramps, nausea and/or vomiting, unpleasant taste/unusual feeling on tongue.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon (≥1/1000, &lt;1/100)</td>
<td>Diarrhoea, constipation, abdominal bloating/noises, dry mouth.</td>
</tr>
</tbody>
</table>

### Skin and subcutaneous tissue disorders

| Uncommon (≥1/1000, <1/100)      | Itching. |

### Musculoskeletal and connective tissue disorders

| Uncommon (≥1/1000, <1/100)      | Cramp. |

### Renal and urinary disorders

| Uncommon (≥1/1000, <1/100)      | Urine discoloration, urinary tract infection symptoms. |

### Reproductive system and breast disorders

<table>
<thead>
<tr>
<th>Common (≥1/100, &lt;1/10)</th>
<th>Vaginal itching/irritation/burning/numbness, pelvic discomfort, vaginal discharge.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon (≥1/1000, &lt;1/100)</td>
<td>Oedema vulva, menstrual discomfort/irregularities, vaginal spotting/bleeding.</td>
</tr>
</tbody>
</table>

### General disorders and administration site conditions

| Uncommon (≥1/1000, <1/100)      | Fatigue, irritability. |

---

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions is an important way to gather more information to continuously monitor the benefit/risk balance of the medicinal product. Any suspected adverse reactions should be reported to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs Fax: +357 22608649

**4.9 Overdose**

There is no human experience of overdosage with Zidoval vaginal gel. There is no specific treatment. Metronidazole is readily removed from the plasma by haemodialysis.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Gynecological anti-infectives and antiseptics

ATC classification: G01 AF01
Metronidazole is a synthetic antibacterial agent which also possesses amoebicidal activity. Zidoval vaginal gel has been shown \textit{in vivo} to be active against the vaginal pathogens Gardnerella vaginalis and bacteroides species. Significant increases in lactobacilli are observed in bacterial vaginosis patients following therapy with Zidoval.

\textbf{5.2 Pharmacokinetic properties}

Bioavailability studies on the administration of a single 5 gram dose of Zidoval vaginal gel into the vagina of 12 normal subjects showed a mean Cmax serum concentration of 237 nanogram/ml or about 2% of the mean maximum serum concentration of a 500 mg tablet taken orally (mean Cmax = 12,785 ng/ml). Under normal usage, the formulation therefore affords minimal serum concentrations of metronidazole.

Metronidazole has a large apparent volume of distribution and has the ability to penetrate the blood brain barrier and blood cerebro-spinal fluid barrier at concentrations similar to serum concentrations. Metronidazole is metabolised in the liver by side chain oxidation and glucuronide formation and a large portion of the absorbed dose is excreted as metabolites. Both unchanged drug and metabolites are excreted mainly in the urine.

\textbf{5.3 Preclinical safety data}

At high doses metronidazole has been found to be mutagenic in bacteria but not in mammalian cells \textit{in vitro} or \textit{in vivo}. A carcinogenic potential has been demonstrated in mouse and rat but not in hamster. In epidemiological studies, no evidence of increased risk of cancer as a consequence of exposure to metronidazole has been observed.

\section*{6. PHARMACEUTICAL PARTICULARS}

\textbf{6.1 List of excipients}

Carbomer (Carbopol) 974P, disodium edetate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, propylene glycol, sodium hydroxide, purified water.

\textbf{6.2 Incompatibilities}

None known

\textbf{6.3 Shelf life}

3 years

\textbf{6.4 Special precautions for storage}

Do not store above 25 °C.

\textbf{6.5 Nature and contents of container}

Aluminium tubes lined with an epoxy phenolic resin with polyethylene screw caps containing 40 g product. The product is packaged with 5 disposable vaginal applicators, each to deliver 5 g of gel.

\textbf{6.6 Special precautions for disposal}

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

\section*{7. EXCEPTIONAL MARKETING AUTHORISATION HOLDER}

C.G. Papaloisou Ltd, 35 Kilkis Avenue, 2234 Cyprus
8. EXCEPTIONAL MARKETING AUTHORISATION NUMBER(S)
   S00343

   DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
   18 January 2007 / 17 January 2013

9. DATE OF REVISION OF THE TEXT

   UK/January 2016